In addition, preservation of endogenous insulin production in T1D patients receiving alefacept, a CD2-blocking Ab, correlates with an increase in CD8+ T cells displaying an exhausted phenotype, marked by PD-1 and Eomes expression (70). Here, CD2 is linked to type 1 diabetes mellitus.